


RESTRICTION REQUIREMENT

The Office requested election of a single compound and a single clinical condition for search and examination. In their response to the first restriction requirement (filed December 15, 2003), Applicants elected 3 β -hydroxy-17 β -aminoandrost-5-ene as the compound and neutropenia as the clinical condition. Applicants hereby reiterate this election of these species for examination. New claims 59 and 61 specify that the neutropenia is associated with radiation exposure. Claims 53 and 56 both recite the elected compound. Claims 1, 6, 7, 9-11, 13, 14 and 46-61 read on this chemical species. Amended claim 49 defines substituents that may be used for the present restriction. The elected compound has the structure



Conclusion

Applicants' representative can be reached at the number given below if the Office has any questions or would like to address any other matters that may arise.

Respectfully submitted,

Dated: 6-14-06

Daryl D Muenchau

Daryl D. Muenchau, Reg. No. 36,616
Hollis-Eden Pharmaceuticals, Inc.
4435 Eastgate Mall, Suite 400
San Diego, CA 92121
(P): 858-320-2569